$35.91
1.45%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
US6402681083
Symbol
NKTR

Nektar Therapeutics Stock price

$36.44
+0.66 1.84% 1M
-31.99 46.75% 6M
-5.84 13.81% YTD
-23.14 38.84% 1Y
+28.87 381.34% 3Y
-162.91 81.72% 5Y
-172.21 82.54% 10Y
-203.56 84.82% 20Y
Nasdaq, Closing price Mon, Nov 16 2026
-0.83 2.23%
ISIN
US6402681083
Symbol
NKTR
Industry

Is Nektar Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$617.2m
Net debt
positive
Cash
$684.3m
Shares outstanding
34.1m
Valuation
P/E
negative
P/S | estimate
22.8 | 29.2
EV/Sales | estimate
11.3 | 14.5
EV/FCF | ex SBC
negative | negative
P/B
1.4
Financial Health
Equity Ratio
32.0%
Return on Equity
-182.7%
ROCE
-12.8%
ROIC
-
Debt/Equity
0.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$12.0m | 22.0%
SBC as % of FCF
-
SBC Growth 1Y
-31.8%
Share Count Growth 1Y
173.9%
Shareholder Yield
-
Financials
Revenue | estimate
$54.6m | $42.6m
EBITDA
$-130.0m
EBIT
$-130.6m
Net Income
$-157.1m
Free Cash Flow | ex SBC
$-234.7m | $-246.7m
Growth
Revenue | estimate
-27.2% | -22.9%
EBITDA
5.3%
EBIT
6.1%
Net Income
-28.5%
Free Cash Flow
-26.2%
Margin
Gross
-
EBITDA
-238.1%
EBIT
-239.3%
Net
-287.8%
Free Cash Flow | ex SBC
-430.0% | -452.0%
More
EPS
$-4.8
FCF per Share
$-6.9
Short interest
21.8%
Employees
63
Rev per Employee
$880.0k

Nektar Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Nektar Therapeutics forecast:

16x Buy
76%
5x Hold
24%

Analyst Opinions

21 Analysts have issued a Nektar Therapeutics forecast:

Buy
76%
Hold
24%

Nektar Therapeutics Events

Past Events
NOV
12
Q3 2026 Earnings Call
5 days ago
OCT
1
Shareholder/Analyst Call - Nektar Therapeutics
about 2 months ago
AUG
13
Q2 2026 Earnings Call
3 months ago
MAY
7
Q1 2026 Earnings Call
6 months ago
APR
20
Special Call - Nektar Therapeutics
7 months ago
MAR
12
Q4 2025 Earnings Call
8 months ago
FEB
10
Special Call - Nektar Therapeutics
9 months ago
DEC
16
Special Call - Nektar Therapeutics
11 months ago
NOV
6
Q3 2025 Earnings Call
about one year ago

Financial data from Nektar Therapeutics

Jun '26
+/-
%
55 55
27% 27%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 53 53
31% 31%
98%
- Research and Development Expense 132 132
6% 6%
241%
-130 -130
5% 5%
-238%
- Depreciation and Amortization 0.69 0.69
65% 65%
1%
EBIT (Operating Income) EBIT -131 -131
6% 6%
-239%
Net Profit -157 -157
29% 29%
-288%

In millions USD.

Don't miss a Thing! We will send you all news about Nektar Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nektar Therapeutics Stock News

Neutral
PRNewsWire
●
5 days ago
SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared to $245.8 million on December 31, 2025.
Neutral
PRNewsWire
●
25 days ago
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common stock and 2,775 restricted stock units (RSUs) to sixteen newly-hired employees under Nektar's 2025 Induceme...
More Nektar Therapeutics News

Company Profile

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The firm focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Head office United States
CEO Mr. Robin
Employees 63
Founded 1990
Website www.nektar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today